EFFECTS OF ACTIVE HCV REPLICATION ON NEUROLOGIC STATUS IN HIV RNA VIRALLY SUPPRESSED PATIENTS
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with interest the article by Clifford et al.,1 who conducted a retrospective study of neurocognitive deficits and peripheral neuropathy in subjects with stable, treated HIV infection and active hepatitis C infection (HCV).
The authors compared the subjects using the Trail-Making A and B tests and the Wechsler Adult Intelligence Scale–Revised (WAIS-R) digit symbol test. No significant differences between groups were observed, which led authors to conclude that active HCV infection does not affect neurocognitive function in subjects with optimally controlled HIV infection. However, additional factors may have influenced results.
Evaluating neurocognitive dysfunction in chronic HCV is challenging and the assessment tools used by Clifford et al. may have been suboptimal. Studies that have demonstrated cognitive differences between viremic HCV-positive and HCV-negative individuals have utilized extensive batteries of cognitive tests that have assessed performance of cognitive domains individually and with high precision.2,3
It has been shown that there is executive function impairment in HCV-positive individuals with minimal or absent HCV-related liver disease.2,3 Using less detailed tools may lead to inadequate findings. Córdoba et al.4 concluded that their use of noncomputerized assessments with inferior sensitivity may have …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patientsD. B. Clifford, M. Smurzynski, L. S. Park et al.Neurology, July 27, 2009 -
Articles
Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamineM. Cherner, S. Letendre, R. K. Heaton et al.Neurology, April 07, 2005 -
Articles
Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIVC.L. Cherry, J.S. Affandi, B.J. Brew et al.Neurology, May 10, 2010 -
Article
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peopleDavid B. Clifford, Florin Vaida, Yu-Ting Kao et al.Neurology, December 10, 2014